@article{3eb79a64f4bf42cf9823a7c240892924,
title = "Pre-treatment attentional processing speed and antidepressant response to transcranial direct current stimulation: Results from an international randomized controlled trial",
abstract = "Background: Transcranial direct current stimulation (tDCS) has promising antidepressant effects, however, clinical trials have shown variable efficacy. Pre-treatment neurocognitive functioning has previously been identified as an inter-individual predictor of tDCS antidepressant efficacy. Objective: In this international multicentre, sham-controlled study, we investigated this relationship while also assessing the influence of clinical and genotype (BDNF Val66Met and COMT Val158Met polymorphisms) factors as predictors of response to active tDCS. Methods: The study was a triple-masked, parallel, randomized, controlled design across 6 international academic medical centers. Participants were randomized to active (2.5 mA) or sham (34 μA) tDCS for 30 min each session for 20 sessions. The anode was centered over the left dorsolateral prefrontal cortex at F3 (10/20 EEG system) and the cathode over the lateral right frontal area at F8. Results: Better pre-treatment attentional processing speed on the Ruff 2 & 7 Selective Attention Test (Total Speed: β = 0.25, p <.05) and concurrent antidepressant medication use (β = 0.31, p <.05) predicted antidepressant efficacy with active tDCS. Genotype differences in the BDNF Val66Metand COMT Val158Met polymorphisms were not associated with antidepressant effects. Secondary analyses revealed that only participants in the highest performing Ruff 2 & 7 Total Speed group at pre-treatment in both active and sham tDCS conditions showed significantly greater antidepressant response compared to those with lower performance at both the 2 and 4 week treatment time points (p <.05). Conclusions: These results suggest that high pre-treatment attentional processing speed may be relevant for identifying participants more likely to show better tDCS antidepressant response to both high (2.5 mA) and very low (34 μA) current intensity stimulation. Clinical trials registration: www.clinicaltrials.gov, NCT01562184.",
keywords = "Cognition, Depression, Genotype, Response, Transcranial direct current stimulation",
author = "Martin, {Donel M.} and McClintock, {Shawn M.} and Aaronson, {Scott T.} and Angelo Alonzo and Husain, {Mustafa M.} and Lisanby, {Sarah H.} and McDonald, {William M.} and Adith Mohan and Stevan Nikolin and John O'Reardon and Weickert, {Cynthia Shannon} and Loo, {Colleen K.}",
note = "Funding Information: Duke University: Richard Weiner, Steven Szabo, Michael Koval, Gabriela Asturias, Jonathan Young, Annie Jayanth, Chris Sikes-Keilp, Michael Olson, Susan Hilbig, Lis Bernhardt, Rosa Jou-Zhang; Emory University: Gail Galendez Snead, Gregory Job, Michele Miles; Rowan University: Amanda Helmer, Michelle Nagurney; Sheppard Pratt Health System: Kathleen Conway; University of New South Wales: Stevan Nikolin, Kerrie-Anne Ho, Taariq Chew, Shani Lauf, Roxanne Cadiz, Lucy McGuirk, Eileen Stech, Bronwyn Hegarty, Joyce Teng, Kevin Yeung, Jessica Sloey, Rosalyn Lai, Laura Cotiga, Duncan George, James Goldstein, Cristal Oxley; University of Texas Southwestern: Paige Baker, Najeeb Ranginwalla, Aatika Parwaiz. Funding Information: Dr. Husain reports research grant support from: NIH, NIMH, NIDA, NINDS, NIA, NARSD, Stanley Medical Foundation, Cyberonics, Neuronetics (past), St. Jude Medical/Abbott. Funding Information: Dr. McClintock reports research support from the National Institutes of Health, honoraria from TMS Health Solutions, and is a Consultant to Pearson. Funding Information: This trial was supported by a Stanley Medical Research Foundation Research grant for investigator initiated research, awarded to Dr Loo and colleagues. Equipment for the study was provided by the Soterix Medical company. Soterix Medical had no role in study design, data collection, analysis, interpretation or reporting of results. Likewise, the study sponsor, the University of New South Wales (Australia) had no role in study design, data collection, analysis, interpretation or reporting of results. Funding Information: Dr Shannon Weickert is funded by the NSW Ministry of Health, Office of Health and Medical Research. CSW is a recipient of a National Health and Medical Research Council (Australia) Principal Research Fellowship (PRF) (#1117079). She is on an advisory board for Lundbeck, Australia Pty Ltd and in collaboration with Astellas Pharma Inc., Japan. Funding Information: Dr. McDonald reports research support from the National Institute of Mental Health, National Institute of Neurological Disease and Stroke, Patient-Centered Outcomes Research Institute, Stanley Foundation, Soterix, Neuronetics and Cervel Neurotherapeutics. He is also a consultant on the Neurological Devices Panel of the Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration and member of an ad hoc member of several NIMH and NINDS study sections. He has a contract with Oxford University Press to co-edit a book on the Clinical Guide to Transcranial Magnetic Stimulation in the Treatment of Depression and section editor for Current Psychiatry Reports. Funding Information: Dr. Martin is the recipient of a NARSAD Young Investigator Award from the Brain and Behavior Foundation, travel support from Miyuki Giken and a speaker's honorarium from Lundbeck. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2018",
month = nov,
day = "1",
doi = "10.1016/j.brs.2018.08.011",
language = "English (US)",
volume = "11",
pages = "1282--1290",
journal = "Brain Stimulation",
issn = "1935-861X",
publisher = "Elsevier Inc.",
number = "6",
}